Literature DB >> 25700862

[Intravesical gemcitabine for non-muscle invasive bladder cancer].

L-M Krabbe1, S Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25700862     DOI： 10.1007/s00120-015-3779-2

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  8 in total

1.  Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.

Authors:  Andreas Böhle; Herbert Leyh; Christian Frei; Michael Kühn; Reinhold Tschada; Tobias Pottek; Walter Wagner; Helmut H Knispel; Wolfgang von Pokrzywnitzki; Ferruh Zorlu; Karin Helsberg; Birgit Lübben; Victoria Soldatenkova; Clemens Stoffregen; Hartwig Büttner
Journal:  Eur Urol       Date:  2009-06-21       Impact factor: 20.096

2.  Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.

Authors:  Truls Gårdmark; Malcolm Carringer; Eva Beckman; Per-Uno Malmström
Journal:  Urology       Date:  2005-09       Impact factor: 2.649

3.  The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.

Authors:  Paolo Gontero; Marco Oderda; Anja Mehnert; Alberto Gurioli; Francesco Marson; Ilaria Lucca; Michael Rink; Marianne Schmid; Luis A Kluth; Giovanni Pappagallo; Filippo Sogni; Francesco Sanguedolce; Riccardo Schiavina; Giuseppe Martorana; Shahrokh F Shariat; Felix Chun
Journal:  J Urol       Date:  2013-03-29       Impact factor: 7.450

4.  Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study.

Authors:  Massimo Porena; Michele Del Zingaro; Massimo Lazzeri; Luigi Mearini; Antonella Giannantoni; Vittorio Bini; Elisabetta Costantini
Journal:  Urol Int       Date:  2010-02-17       Impact factor: 2.089

5.  Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study.

Authors:  Maurizio A Brausi; Paolo Gontero; Vincenzo Altieri; Renzo Colombo; Ilaria Conti; Aldo Vittorio Bono
Journal:  Urol Int       Date:  2011-11-11       Impact factor: 2.089

6.  [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].

Authors:  Ming Cao; Chen-kai Ma; Jun Ma; Hai-ge Chen; Wei Xue
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2011-05

7.  Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.

Authors:  Giuseppe Di Lorenzo; Sisto Perdonà; Rocco Damiano; Adriana Faiella; Francesco Cantiello; Sandro Pignata; Paolo Ascierto; Ester Simeone; Marco De Sio; Riccardo Autorino
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

8.  Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

Authors:  Raffaele Addeo; Michele Caraglia; Sergio Bellini; Alberto Abbruzzese; Bruno Vincenzi; Liliana Montella; Antonio Miragliuolo; Rosario Guarrasi; Michele Lanna; Gregorio Cennamo; Vincenzo Faiola; Salvatore Del Prete
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.